J. Mckenney

J. Mckenney, J. Bisognano, K. Maki, 2008, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia

J. Mckenney, D. Rader, W. Sasiela, 2008, Nature Clinical Practice Cardiovascular Medicine.

Will torcetrapib be the next big thing in coronary heart disease risk reduction?

J. Mckenney, J. Hoekstra, 2007, Current atherosclerosis reports.

Effect of advanced pharmaceutical services on the incidence of adverse drug reactions.

J. Mckenney, A. Wasserman, 1979, American journal of hospital pharmacy.

Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients.

J. D. Proctor, J. Mckenney, J. Wright, 1993, Clinical pharmacy.

The Effect of Low‐Dose Hydrochlorothiazide on Blood Pressure, Serum Potassium, and Lipoproteins

D. G. Aycock, J. Mckenney, N. Rifai, 1986, Pharmacotherapy.

Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.

J. Mckenney, J. Guyton, D. Nash, 2000, Archives of internal medicine.

Comparison of gemfibrozil and lovastatin in patients with high low-density lipoprotein and low high-density lipoprotein cholesterol levels.

J. Mckenney, Jackson T. Wright, M. Barnett, 1992 .

The Effect of Supplemental Dietary Fat on Plasma Cholesterol Levels in Lovastatin‐Treated Hypercholesterolemic Patients

J. D. Proctor, J. Mckenney, J. Wright, 1995, Pharmacotherapy.

An evaluation of cholesterol screening in community pharmacies.

J. Mckenney, 1993, American Pharmacy.

New Guidelines for Managing Hypercholesterolemia: Revised guidelines for detecting, evaluating, and treating high blood cholesterol reflect new understanding and treatment of the condition and associated risk.

J. Mckenney, 1993 .

Alternative Pharmacologic Approaches to the Initial Management of Hypertension

J. Mckenney, 1985, Drug intelligence & clinical pharmacy.

Analytic and Clinical Performance of Two Compact Cholesterol‐Testing Devices

J. Mckenney, W. Miller, D. Volles, 1998, Pharmacotherapy.

Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals.

J. Mckenney, W. Insull, H. Schrott, 2004, The American journal of cardiology.

Combination therapy with prescription omega-3-acid ethyl esters and statin improves non-HDL-C more effectively than statin alone

J. Mckenney, K. Maki, R. Doyle, 2010 .

Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.

J. Mckenney, H. Bays, A. Tershakovec, 2012, Metabolic syndrome and related disorders.

Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.

J. Mckenney, E. Schaefer, L. McCormick, 2001, The American journal of cardiology.

Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials.

J. Mckenney, H. Bays, G. Gleim, 2015, Journal of clinical lipidology.

Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).

J. Mckenney, D. Gaudet, E. Stein, 2014, The American journal of cardiology.

Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients

J. Mckenney, E. Stein, H. Bays, 2010, Current medical research and opinion.

Renin profile, race, and antihypertensive efficacy with atenolol and labetalol.

J. Mckenney, J. Wright, D. DiPette, 1991, Journal of human hypertension.

Atherosclerosis in a managed care plan: hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring.

J. Mckenney, K. Fox, R. Ohsfeldt, 2009, Journal of clinical lipidology.

From research into practice: how should healthcare organizations/governments decide about lipid therapy and who will pay? Reactor panel and open forum.

J. Mckenney, J. Hay, P. Langley, 1998, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Commentary on Langley and McKenney Papers.

J. Mckenney, J. Hay, P. Langley, 1998, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Methods of Modifying Compliance Behavior in Hypertensive Patients

J. Mckenney, 1981, Drug intelligence & clinical pharmacy.

The National Lipid Association surveys of consumers, physicians, and pharmacists regarding an over-the-counter statin in the United States: is this a good idea?

J. Mckenney, Jerome D. Cohen, W. Brown, 2004, The American journal of cardiology.

Pharmacotherapy of dyslipidemia in postmenopausal women: weighing the evidence.

J. Mckenney, M. Crouch, D. Brophy, 1999, Journal of women's health & gender-based medicine.

Effectofomega-3-acidethyl estersonsteady-stateplasma pharmacokineticsofatorvastatin inhealthyadults

J. Mckenney, G. Morelli, R. Doyle, 2008 .

Use of A Treatment Algorithm to Achieve NCEP ATP III Goals With Atorvastatin

J. Mckenney, P. Thompson, H. Bays, 2005, Journal of cardiovascular pharmacology.

Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.

J. Mckenney, G. Fonarow, C. Ballantyne, 2005, The American journal of cardiology.

Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.

J. Mckenney, N. Lalwani, D. Macdougall, 2021, Journal of clinical lipidology.

Comparison of gemfibrozil and lovastatin in patients with high low-density lipoprotein and low high-density lipoprotein cholesterol levels.

J. Mckenney, J. Wright, M. Barnett, 1992, Archives of internal medicine.

Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.

J. Mckenney, B. Gumbiner, H. Bays, 2006, Journal of the American College of Cardiology.

Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II).

J. Mckenney, C. Cannon, D. Blom, 2017, The American journal of cardiology.

Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.

J. Mckenney, D. Hunninghake, J. Wright, 1994, Archives of internal medicine.

Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo

J. Mckenney, P. Joshi, S. Martin, 2016, Lipids in Health and Disease.

Understanding PCSK9 and anti-PCSK9 therapies.

J. Mckenney, 2015, Journal of clinical lipidology.

Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis

J. Mckenney, R. Wu, R. Dufour, 2015, Postgraduate medicine.

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial)

J. Mckenney, E. Stein, H. Bays, 2003 .

Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial.

J. Mckenney, C. Cannon, J. Robinson, 2016, Journal of clinical lipidology.

Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy.

J. Mckenney, C. Ballantyne, N. Lalwani, 2016, The American journal of cardiology.

Niacin for dyslipidemia: considerations in product selection.

J. Mckenney, 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Efﬁcacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

J. Mckenney, C. Cannon, D. Blom, 2015 .

Lovastatin: a new cholesterol-lowering agent.

J. Mckenney, 1988, Clinical pharmacy.

TREATING TO CHOLESTEROL TARGETS IN SPECIAL POPULATIONS The following are excerpts from a roundtable discussion with faculty chair

J. Mckenney, Theodore Feldman, P. Kwiterovich, 2002 .

The Effect of Low‐Dose Phenytoin on High‐Density Lipoprotein Cholesterol

J. Mckenney, J. Wright, G. C. Briggs, 1992, Pharmacotherapy.

JCL roundtable: PCSK9 inhibitors in clinical practice.

J. Mckenney, W. Brown, P. Moriarty, 2016, Journal of clinical lipidology.

Understanding physician and consumer attitudes concerning cholesterol management: results from the National Lipid Association surveys.

J. Mckenney, R. Pasternak, Jerome D. Cohen, 2004, The American journal of cardiology.

MANAGEMENT OF DYSLIPIDEMIA : IMPLICATIONS OF THE ADULT TREATMENT PANEL ( ATP ) III RECOMMENDATIONS —

J. Mckenney, 2001 .

Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.

J. Mckenney, K. Maki, B. Lubin, 2008, The American journal of cardiology.

Pharmacologic characteristics of statins

J. Mckenney, 2003, Clinical cardiology.

Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol.

J. Mckenney, H. Bays, H. Schrott, 2003, The American journal of cardiology.

Impact of an Electronic Medication Compliance Aid on Long‐Term Blood Pressure Control

W. P. Munroe, J. Mckenney, Jackson T. Wright, 1992, Journal of clinical pharmacology.

Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.

J. Mckenney, P. Barter, D. Hunninghake, 2004, American Journal of Cardiology.

LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.

J. Mckenney, C. Ballantyne, W. Brady, 2005, MedGenMed : Medscape general medicine.

Glycemic and Blood Pressure Responses to Acute Doses of Rebaudioside A, a Steviol Glycoside, in Subjects with Normal Glucose Tolerance or Type 2 Diabetes Mellitus

J. Mckenney, B. Zinman, J. Gerich, 2009 .

Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus.

J. Mckenney, K. Maki, S. Schwartz, 2008, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.

J. D. Proctor, J. Mckenney, S. Harris, 1994, JAMA.

Drug-related hospital admissions.

J. Mckenney, W. L. Harrison, 1976, American journal of hospital pharmacy.

The Effect of Ranitidine and Cimetidine on Single‐dose Diltiazem Pharmacokinetics

J. Mckenney, J. Wright, J. Wood, 1985, Pharmacotherapy.

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

J. Mckenney, E. Stein, D. Kereiakes, 2012, Journal of the American College of Cardiology.

Alirocumab in high-risk patients: Observations from the open-label expanded use program.

Alan S. Brown, J. Mckenney, A. Goldberg, 2018, Journal of clinical lipidology.

Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).

J. Mckenney, M. McGovern, H. Bays, 2007, Atherosclerosis.

Safety considerations with fibrate therapy.

J. Mckenney, M. Davidson, A. Armani, 2007, The American journal of cardiology.

Statin safety: an assessment using an administrative claims database.

J. Mckenney, M. Fisher, V. Willey, 2006, The American journal of cardiology.

Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

J. Mckenney, J. Guyton, M. Davidson, 2006, The American journal of cardiology.

Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.

J. Mckenney, E. Stein, Eli M Roth, 2012, The New England journal of medicine.

Role of Prescription Omega‐3 Fatty Acids in the Treatment of Hypertriglyceridemia

J. Mckenney, D. Sica, 2007, Pharmacotherapy.

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

Elinor Miller, J. Mckenney, E. Stein, 2003, The American journal of cardiology.

The effect of high‐dose short‐term ibuprofen on antihypertensive control with hydrochlorothiazide

L. W. Cooper, J. Mckenney, J. Wright, 1989, Clinical pharmacology and therapeutics.

The Effect of Phenylpropanolamine on 24-Hour Blood Pressure in Normotensive Subjects Administered Indomethacin

J. Mckenney, R. Goodman, J. Wight, 1991, DICP : the annals of pharmacotherapy.

Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia.

J. Mckenney, D. Sica, 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Total error assessment of five methods for cholesterol screening.

J. Mckenney, V. M. Chinchilli, W. Miller, 1993, Clinical chemistry.

Clinical Evaluation of a Finger Oscillometric Blood Pressure Device

W. P. Munroe, J. Mckenney, Jefferson M. Sesler, 1991, DICP : the annals of pharmacotherapy.

Something important is missing in the ACC/AHA cholesterol treatment guidelines.

J. Mckenney, 2015, Journal of the American Pharmacists Association : JAPhA.

Potential Nontraditional Applications of Statins

J. Mckenney, 2003, The Annals of pharmacotherapy.

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.

Daniel Bloomfield, J. Mckenney, R. Pasternak, 2009, American heart journal.

National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.

J. Mckenney, S. Grundy, Matthew K. Ito, 2015, Journal of clinical lipidology.

Low‐dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low‐density lipoprotein cholesterol in patients with primary hypercholesterolemia

J. Mckenney, D. Hunninghake, J. Isaacsohn, 2001, Clinical cardiology.

Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists.

Alan S. Brown, J. Mckenney, C. Ballantyne, 2011, Journal of clinical lipidology.

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2.

J. Mckenney, S. Grundy, S. Daniels, 2015, Journal of clinical lipidology.

New perspectives on the use of niacin in the treatment of lipid disorders.

J. Mckenney, 2004, Archives of internal medicine.

Efficacy and safety of rosuvastatin in treatment of dyslipidemia.

J. Mckenney, 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Maintaining Cardiovascular Health in Patients With Mixed Dyslipidemia Optimizing the Management of Hypertriglyceridemia and Non-HDL Cholesterol

J. Mckenney, Matthew K. Ito, E. Brinton, 2009, Journal of Managed Care Pharmacy : JMCP.

Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial

J. Mckenney, P. Jones, V. Cain, 2003, Current medical research and opinion.

Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).

J. Mckenney, R. Karas, C. Ballantyne, 2008, The American journal of cardiology.

Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study.

J. Mckenney, R. Karas, C. Ballantyne, 2008, Journal of Clinical Lipidology.

A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.

J. Mckenney, L. McCormick, S. Weiss, 1998, The American journal of medicine.

Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined With Colestipol

J. Mckenney, H. Schrott, A. Sniderman, 1996, Journal of cardiovascular pharmacology and therapeutics.

Pharmaceutical care services and results in project ImPACT: hyperlipidemia.

J. Mckenney, M. Cziraky, B. Bluml, 2000, Journal of the American Pharmaceutical Association.

Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.

J. Mckenney, M. Davidson, D. Maccubbin, 2013, International journal of cardiology.

The Cost of Treating Dyslipidaemia Using National Cholesterol Education Program (NCEP) Guidelines

J. Mckenney, 2012, PharmacoEconomics.

Safety of extended-release niacin/laropiprant in patients with dyslipidemia.

J. Mckenney, C. Ballantyne, J. Paolini, 2010, Journal of clinical lipidology.

Effect of drugs on high-density lipoprotein.

J. Mckenney, 2007, Journal of clinical lipidology.

New Cholesterol Guidelines, New Treatment Challenges

J. Mckenney, 2002, Pharmacotherapy.

The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients

J. Mckenney, D. Hunninghake, S. Weiss, 1998, PharmacoEconomics.

The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study.

J. Mckenney, E. Stein, L. Shurzinske, 1996, Clinical therapeutics.

Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.

J. Mckenney, H. Hutchinson, H. Bays, 2002, American heart journal.

National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.

J. Mckenney, S. Grundy, Matthew K. Ito, 2014, Journal of clinical lipidology.

Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin.

J. Mckenney, E. Stein, H. Bays, 2010, Mayo Clinic proceedings.

Torcetrapib/atorvastatin combination therapy

J. Mckenney, H. Bays, M. Davidson, 2005, Expert review of cardiovascular therapy.

Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia

J. Mckenney, L. Williams, A. Gold, 2010, American journal of cardiovascular drugs : drugs, devices, and other interventions.

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

J. Mckenney, E. Stein, H. Schrott, 1997, The American journal of cardiology.

Interim report from project ImPACT: hyperlipidemia.

J. Mckenney, R. Elswick, M. Cziraky, 1998, Journal of the American Pharmaceutical Association.

A softgel dietary supplement containing esterified plant sterols and stanols improves the blood lipid profile of adults with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled replication study.

J. Mckenney, C. Cook, K. Maki, 2014, Journal of the Academy of Nutrition and Dietetics.

Plant Sterols and Stanols Improves the Blood Lipid Pro fi le of Adults with Primary Hypercholesterolemia : A Randomized , Double-Blind , Placebo-Controlled Replication Study

J. Mckenney, C. Cook, K. Maki, 2013 .

Update on the National Cholesterol Education Program Adult Treatment Panel III Guidelines: Getting to Goal

J. Mckenney, 2003, Pharmacotherapy.

Effects of simvastatin, an HMG‐CoA reductase inhibitor, in patients with hypertriglyceridemia

J. Mckenney, R. Krauss, A. Dobs, 2003, Clinical cardiology.

The Effect of Clinical Pharmacy Services on Patients with Essential Hypertension

J. Mckenney, M. Barr, H. Henderson, 1973, Circulation.

Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases.

J. Mckenney, E. Ming, M. Marotti, 2008, Journal of clinical lipidology.

Combination Treatment with Atorvastatin plus Niacin Provides Effective Control of Complex Dyslipidemias: A Literature Review

J. Mckenney, 2012, Postgraduate medicine.

Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.

J. Mckenney, D. Karalis, P. Jones, 2005, American heart journal.

Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction.

J. Mckenney, 2002, The American journal of cardiology.

The effect of phenylpropanolamine on ambulatory blood pressure

J. Mckenney, J. Wright, C. Barlascini, 1986, Clinical pharmacology and therapeutics.

Effect of telephone follow-up on medication compliance.

J. Mckenney, K. C. Steiner, W. Garnett, 1981, American journal of hospital pharmacy.

Economic benefits of aggressive lipid lowering: a managed care perspective.

J. Mckenney, B. Kinosian, 1998, The American journal of managed care.

Treatment of High-Risk patients with ezetimibe plus simvastatin Co-Administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III Low-Density lipoprotein cholesterol goals

J. Mckenney, W. Insull, H. Schrott, 2004 .

Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting.

J. Mckenney, M. Fisher, V. Willey, 2013, Journal of clinical lipidology.

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.

J. Mckenney, C. Shear, J. Revkin, 2006, Journal of the American College of Cardiology.

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

J. Mckenney, C. Cannon, D. Blom, 2015, European heart journal.

Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.

J. Mckenney, K. Fox, R. Ohsfeldt, 2006, The American journal of managed care.

Once‐daily pravastatin in patients with primary hypercholesterolemia: A dose‐response study

J. D. Proctor, J. Mckenney, J. Farmer, 1991, Clinical cardiology.

Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis.

J. Mckenney, C. Ballantyne, E. Stein, 2001, Clinical therapeutics.

Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose

J. Mckenney, K. Maki, M. Farmer, 2009 .

Drug therapy assessments by pharmacists.

D. Atkins, J. Mckenney, M. E. Carasiti, 1980, American journal of hospital pharmacy.

ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks.

J. Mckenney, E. Roth, 2015, Future cardiology.

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance.

J. Mckenney, P. Thompson, C. Ballantyne, 2016, Journal of clinical lipidology.

THE EFFECTS OF CO-ADMINISTERING A MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 SERINE PROTEASE, REGN727/SAR236553, WITH 10 AND 80 MG ATORVASTATIN COMPARED TO 80 MG ATORVASTATIN ALONE IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (NCT: 01288469)

J. Mckenney, E. Stein, C. Hanotin, 2012 .

The effects of benazepril, a new angiotensin‐converting enzyme inhibitor, in mild to moderate essential hypertension: A multicenter study

J. Mckenney, A. Leon, M. Sambhi, 1991, Clinical pharmacology and therapeutics.

Effect of High-Dose Ibuprofen on 24-Hour Blood Pressure in Healthy Women

J. Mckenney, N. Yunker, R. Goodman, 1987, Drug intelligence & clinical pharmacy.

Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy

J. Mckenney, D. Kereiakes, D. Winegar, 2015, Journal of the American Heart Association.

Lipid Lowering With Bempedoic Acid Added to Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: A Randomized Controlled Trial

J. Mckenney, D. Macdougall, Stephanie Kelly, 2019, Journal of Clinical Lipidology.

Study of the Pharmacokinetic Interaction Between Simvastatin and Prescription Omega‐3‐Acid Ethyl Esters

J. Mckenney, R. Shalwitz, C. Pantaleon, 2006, Journal of clinical pharmacology.

Effect of PCSK 9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy

J. Mckenney, D. Kereiakes, D. Winegar, 2015 .

The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia

J. Mckenney, H. Bays, K. Thakker, 2010, Diabetes Care.

Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo

J. Mckenney, P. Joshi, S. Martin, 2016, Lipids in Health and Disease.

Use of antihypertensive agents in patients with glucose intolerance.

J. Mckenney, J. Wright, R. Goodman, 1985, Clinical pharmacy.

Office-Based Cholesterol Testing: Impact on Process-of-Care in Patients with Hypercholesterolemia a Pilot Study

J. Mckenney, D. Ruffin, 1997 .

Patient education and compliance: how to make it cost-effective.

J. Mckenney, 1998, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Effects of diltiazem hydrochloride on glucose tolerance in persons at risk for diabetes mellitus.

J. Mckenney, J. Wright, B. J. Jones, 1988, Clinical pharmacy.

Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.

J. Mckenney, 2005, The American journal of cardiology.

Pharmacy management of hypertensive patients.

J. Mckenney, 1974, Journal of the American Pharmacists Association.

ASHP Therapeutic Position Statement on the safe use of niacin in the management of dyslipidemias. American Society of Health-System Pharmacists.

J. Mckenney, M. Britton, J. Bradberry, 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

National Lipid Association Annual Summary of Clinical Lipidology 2016.

J. Mckenney, A. Goldberg, H. Bays, 2016, Journal of clinical lipidology.

Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes , impaired or normal fasting glucose

J. Mckenney, K. Maki, M. Farmer, 2009 .

J. Mckenney, C. Cannon, D. Blom, 2015, European heart journal.

Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose

J. Mckenney, K. Maki, M. Farmer, 2009, Nutrition journal.

Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia

J. Mckenney, Stacey L. Abby, Michael R. Jones, 2005, Current medical research and opinion.

An assessment of statin safety.

J. Mckenney, 2006, The American journal of managed care.

Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia.